Alzheimer's disease: Can exercise prevent memory loss?.Understanding the difference between dementia types.Benefits of and barriers to pharmacogenomics―Guided treatment for major depressive disorder. Discontinuing antidepressant medications in adults. Suicidality in children and adolescents being treated with antidepressant medications.A reassessment of the safety profile of monoamine oxidase inhibitors: Elucidating tired old tyramine myths. International Journal of Molecular Sciences. The serotonin syndrome: From molecular mechanisms to clinical practice. What is pharmacogenomics? Genetics Home Reference. Privileged scaffolds as MAO inhibitors: Retrospect and prospects. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for management of treatment-resistant depression. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Monoamine oxidase inhibitors: A clinical colloquy. Seek immediate medical attention if you have any of these signs or symptoms.
0 Comments
Leave a Reply. |